Company*
(Symbol)

Product

Description

Indication

Status (Date)


CANCER

Alizyme
plc
(UK; LSE:AZM)

ATL-104

Acts by stimulating the growth of cells lining the mouth

Mucositis in cancer patients

Company completed the Phase Ia trial (1/23**)

Biomira Inc.
(Canada;
BIOM)

BLP25

Vaccine; synthetic MUC1 therapeutic vaccine consisting of 25-amino-acid sequence of the MUC1 cancer mucin, encapsulated in liposomes

Non-small-cell
lung cancer

An independent Data Safety Monitoring Board recommended the Phase IIb trial continue at centers in Canada and the UK (1/30)

Elan Corp.
plc
(Ireland;
NYSE:ELN)

Myocet

Liposomal formulation of doxorubicin

Metastatic
breast cancer

Company received approval for the product in Canada (1/14)

GlycoDesign
Inc.
(Canada;
TSE:GD)

GD0039

Anticancer compound

Metastatic
renal cancer

Survival data from a Phase III trial in Canada showed nine of 18 patients enrolled are alive, and their current median survival since starting GD0039 is 17.2 months (1/22)

Guilford
Pharmaceu-
ticals
Inc.
(GLFD)

Gliadel
Wafer

Biodegradable polyanhydride polymer wafer implant containing carmustine

Malignant
glioma

Company filed a submission in Europe, seeking an expanded indication for Gliadel Wafer for use during initial surgery (1/31)

GW Pharma-
ceuticals plc

(UK; AIM:GWP)

-

Cannabis-based medicine

Cancer pain

Company expanded its Phase III program (1/16)

Onyvax Ltd.
(UK)*

Onyvax P

Therapeutic vaccine designed to provoke the immune system to attack prostate cancer cells

Prostate
cancer

Company began a Phase II trial in the UK (1/9)

PhotoCure
ASA
(Norway;
OSE:PH)

Metvix
PDT

Photodynamic therapy

Basal cell
carcinoma and
actinic keratosis

Company submitted a marketing authorization application to Swiss authorities (1/15)

Progen
Industries Ltd.
(Australia; PGLAF)

PI-88

Anticancer therapeutic; sulfated oligosaccharide

Multiple
myeloma

A Phase II trial began in Melbourne, Australia (1/22)

Therion
Biologics
Corp.*

-

Two-component vaccine targeting the tumor antigen NY-ESO-1; pox-virus-based vaccine

Breast and bladder cancer, melanoma and sarcoma

Company began a European Phase I trial (1/2)

Transgene
SA
(France;
TRGNY)

Adeno
Interferon

Gamma immunotherapeutic
product

Cutaneous
lymphoma

Company initiated a Phase I trial in Switzerland (1/8)

Transgene
SA
(France;
TRGNY)

MVA-
Muc1-
IL2

Vaccine that uses a highly attenuated MVA vaccinia virus vector to express the Muc1 tumor-associated antigen found in most adenocarcinoma and the cytokine interleukin-2 to stimulate specific T-cell responses

Lung cancer and breast cancer

Company began two Phase II trials, one with 66 patients in lung cancer, and the second with 50 patients in breast cancer; trials will be conducted in France, Belgium and Switzerland (1/23)

Viragen Inc.
(AMEX:VRA)

-

Natural human alpha interferon

Hairy-cell leukemia and chronic myelogenous leukemia

The product was approved in Mexico for patients who do not respond to recombinant interferon regimens (1/31)

CARDIOVASCULAR

Forbes Medi-
Tech Inc.
(Canada; FMTI;TSE:FMI)

FM-
VP4

Cholesterol-lowering drug

High cholesterol

Company initiated a Phase I trial in Amsterdam (1/31)

CENTRAL NERVOUS SYSTEM

Prana Bio-
technology
Ltd.
(Australia;
PRNAF; ASX:PBT)

-

Neuroprotection therapy based on oxidation biology and metalloprotein brain chemistry

Alzheimer's disease

Company completed the clinical phase of the trial in Australia (1/22)

INFECTION

Keryx
Biopharma-
ceuticals
Inc.
(KERX)

KRX-
101

Sulodexide

HIV-associated neuropathy

Keryx received approval in South Africa to initiate a Phase II trial (1/29)

MedImmune
Inc.
(MEDI)

Synagis

Palivizumab

To prevent serious lower respiratory tract disease caused by respiratory syncytial virus

Product was approved in Japan (1/24)

INFLAMMATION AND PAIN

AlphaRx Inc.
(Canada; OTC
BB:AHRX)

Flexogan

A series of over-the-counter pain-relieving products using Bioadhesive Colloidal Dispersion delivery technology

Inflammation

Company completed the Canadian marketing registration (1/9)

MISCELLANEOUS

Cephalon Inc.
(CEPH)

Modiodal

Modafinil

Excessive daytime sleepiness associated with narcolepsy

Company received approval to sell and distribute modafinil in Mexico (1/22)

EpiGenesis
Pharmaceu-
ticals
Inc.*

EPI-
2010

The first of a new class of respiratory drugs called Respirable Antisense Oligonucleotides

Asthma

Company released positive results from a trial in London; a single dose reduced the need of the 14 patients in the study to use their bronchodilator medicine to control asthma symptoms (1/23)

Transkaryotic Therapies Inc. (TKTX)

Replagal

Agalsidase alfa; enzyme replacement therapy

Fabry's disease

Company received marketing authorization in Israel, Switzerland and the Czech Republic (1/7)

Viragen
Inc.
(AMEX:
VRA)

Natural alpha interferon responses

Produced by white blood cells; one of the body's natural defensive to recombinant interferon

All diseases in which patients became resistant

Company received Swedish regulatory approval to expand use of its natural alpha interferon (1/17)


Notes:

* Privately held

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AIM = Alternative Investment Market of the London Stock Exchange; AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OSE = Oslo Stock Exchange; TSE = Toronto Stock Exchange